- Home
- BRNS vs INKT Comparison
BRNS vs INKT Comparison
Compare BRNS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRNS | INKT |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 45.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRNS | INKT |
|---|---|---|
| Price | $0.55 | $11.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $35.00 |
| AVG Volume (30 Days) | 33.5K | ★ 157.8K |
| Earning Date | 03-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $6.66 |
| 52 Week High | $2.91 | $76.00 |
Technical Indicators
Market Signals| Indicator | BRNS | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 56.39 |
| Support Level | N/A | $10.94 |
| Resistance Level | $0.76 | $12.64 |
| Average True Range (ATR) | 0.04 | 0.99 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 16.67 | 40.50 |
Price Performance
Historical ComparisonAbout BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.